BR0212527A - Composições de proteìna de matriz esmaltada para modulação de resposta imune - Google Patents

Composições de proteìna de matriz esmaltada para modulação de resposta imune

Info

Publication number
BR0212527A
BR0212527A BR0212527-7A BR0212527A BR0212527A BR 0212527 A BR0212527 A BR 0212527A BR 0212527 A BR0212527 A BR 0212527A BR 0212527 A BR0212527 A BR 0212527A
Authority
BR
Brazil
Prior art keywords
immune response
protein compositions
matrix protein
enameled
response modulation
Prior art date
Application number
BR0212527-7A
Other languages
English (en)
Inventor
Peter Lyngstadaas Stale
Gestrelius Stina
Original Assignee
Biora Bioex Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biora Bioex Ab filed Critical Biora Bioex Ab
Publication of BR0212527A publication Critical patent/BR0212527A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)

Abstract

"COMPOSIçõES DE PROTEìNA DE MATRIZ ESMALTADA PARA MODULAçãO DE RESPOSTA IMUNE". A presente invenção refere-se ao uso de uma preparação de uma substância de matriz esmaltada ativa, tal como uma amelogenina, para a manufatura de uma composição farmacêutica para modulação de uma resposta imune. A composição pode ser usada na prevenção e/ou tratamento de uma condição ou doença em um mamífero a qual é caracterizada pelo dito mamífero apresentar um desequilíbrio na resposta imune nativa aos estímulos internos e/ou externos, isto é, onde pelo menos uma parte do dito sistema imune do mamífero é estimulado de forma não discriminada, reage hipersensivelmente ao dito imunogene, ou falha ao reagir aos ditos estímulos. Dita condição pode tipicamente ou ser sistemática ou local, tal como uma inflamação em todo o corpo sistêmica e/ou pós-traumática ou uma doença auto-imune.
BR0212527-7A 2001-09-14 2002-09-06 Composições de proteìna de matriz esmaltada para modulação de resposta imune BR0212527A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101340 2001-09-14
US32328601P 2001-09-19 2001-09-19
PCT/SE2002/001593 WO2003024479A1 (en) 2001-09-14 2002-09-06 Enamel matrix protein compositions for modulating immune response

Publications (1)

Publication Number Publication Date
BR0212527A true BR0212527A (pt) 2004-10-19

Family

ID=26069064

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212527-7A BR0212527A (pt) 2001-09-14 2002-09-06 Composições de proteìna de matriz esmaltada para modulação de resposta imune

Country Status (13)

Country Link
US (2) US7608284B2 (pt)
EP (1) EP1432435A1 (pt)
JP (1) JP4668534B2 (pt)
CN (1) CN100346823C (pt)
AU (1) AU2002334515B2 (pt)
BR (1) BR0212527A (pt)
CA (1) CA2459773A1 (pt)
HK (1) HK1074770A1 (pt)
IL (2) IL160639A0 (pt)
MX (1) MXPA04002348A (pt)
PL (1) PL369029A1 (pt)
RU (1) RU2295972C2 (pt)
WO (1) WO2003024479A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051457A2 (en) 2009-11-02 2011-05-05 Straumann Holding Ag Purified emd protein composition
WO2011073447A1 (en) 2009-12-18 2011-06-23 Straumann Holding Ag Emd c-depleted
CN103153334B (zh) 2010-10-15 2016-11-16 斯特劳曼控股公司 包含pga的新的emd制剂
WO2012153333A1 (en) 2011-05-09 2012-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Regeneration and repair of mesenchymal tissue using amelogenin
JP2014517693A (ja) * 2011-05-27 2014-07-24 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション 歯科疾患を治療するための試薬および方法
US9861455B2 (en) 2013-07-30 2018-01-09 TI Intellectual Property Inc. Dental implant system
EP3166629B1 (en) 2014-07-09 2019-04-24 Straumann Holding AG Low viscosity emd
CN105037530B (zh) * 2015-07-14 2019-08-02 华南理工大学 一种天然釉原蛋白组分的分离纯化方法
CN111053789A (zh) * 2019-11-26 2020-04-24 湖南营养树生物科技有限公司 调节免疫系统的方法和组合物
WO2022191828A1 (en) * 2021-03-10 2022-09-15 Wen Tan NEW USE OF (R)-β2-AGONISTS IN TREATMENT OF SEPSIS AND ACUTE RESPIRATORY DISTRESS SYNDROME

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2050158C1 (ru) 1991-12-27 1995-12-20 Константин Степанович Десятниченко Препарат для стимулирования физиологической и репаративной регенерации "стимбон-1"
BRPI9908182C1 (pt) * 1998-02-27 2021-05-25 Biora Ab composições de proteína de matriz para cura de feridas
DE69910622T2 (de) * 1998-02-27 2004-06-17 Biora Bioex Ab Matrixprotein enthaltende Zusammensetzungen für entzündliche und infektiöse Zustände
US6979670B1 (en) * 1999-03-10 2005-12-27 Biora Bioex Ab Matrix protein compositions for grafting

Also Published As

Publication number Publication date
WO2003024479A1 (en) 2003-03-27
HK1074770A1 (en) 2005-11-25
US20030077291A1 (en) 2003-04-24
RU2295972C2 (ru) 2007-03-27
IL160639A0 (en) 2004-07-25
PL369029A1 (en) 2005-04-18
US7897180B2 (en) 2011-03-01
RU2004111294A (ru) 2005-03-20
US7608284B2 (en) 2009-10-27
EP1432435A1 (en) 2004-06-30
AU2002334515B2 (en) 2007-01-04
JP4668534B2 (ja) 2011-04-13
CA2459773A1 (en) 2003-03-27
CN1585648A (zh) 2005-02-23
MXPA04002348A (es) 2004-09-28
IL160639A (en) 2008-04-13
CN100346823C (zh) 2007-11-07
JP2005502726A (ja) 2005-01-27
US20100093632A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
BR0212527A (pt) Composições de proteìna de matriz esmaltada para modulação de resposta imune
BR0115180A (pt) Composição de condicionamento do cabelo e método para condicionamento de cabelos
BRPI0110914B8 (pt) 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
BR0315767A (pt) Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
ES2142781T1 (es) Unguento verde.
ATE254928T1 (de) Stabilisierte zusammensetzung mit nootropen wirkstoffen
BR0213107A (pt) Composição de gel macio ou bastão geleificado para reduzir a umidade da axila
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BR0212960A (pt) composição de tabaco mastìgavel e/ou inalável, processo para preparar a mesma, e, substrato
CO5140077A1 (es) Complejo estable insoluble en agua, composiciones farma- ceuticas que lo contienen y metodos para su preparacion . .
ES2063882T5 (es) Hidrolizados de proteinas.
BR0208183A (pt) Peptìdeo modificado por wt1
ES2162917T3 (es) Mejoras en o relativas al suministro de peptidos.
BR9815590A (pt) Roupa de treinamento e de consumo de energia
BR0113091A (pt) Processo para a multiplicação de polipeptìdeos sintetizados quimicamente e processo para a preparação de proteìnas biologicamente ativas
BR9909678A (pt) Aperfeiçoados ensaios de imunodiagnóstico usando agentes redutores
BRPI9805021A (pt) processo para estabilizar proteínas em um processo de congelamento e liofilização ou durante armazenagem em baixas temperaturas, forma de armazenagem e composição farmacêutica.
BR0215048A (pt) Composições farmacêuticas à base de derivados de azetidina
BR9814760A (pt) Proteìna anticongelamento, sequência de ácido nucléico, e, produto alimentìcio.
HUP0002117A2 (hu) Érzéstelenítő vegyület átlátszó, injektálható összetételben
BR9905636A (pt) Processos para preparar um metaloaluminossilicato e para preparar uma composição de aluminossilicato, e, composição de metaloaluminossilicato
BR0215081A (pt) Proteìnas purificadas do envoltório do vìrus de hepatite c para uso diagnóstico e terapêutico
FR2820316B1 (fr) Nouvelles compositions topiques a phase externe huileuse et leur procede de preparation
KR910005876A (ko) 모세혈관 취약증의 치료를 위한 극소용 약학적 조성물
AR046226A1 (es) Formulaciones farmaceuticas que contienen saborizante con caracteristicas farmaceuticas mejoradas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INSTITUT STRAUMANN AG (CH)

Free format text: TRANSFERIDO DE: BIORA BIOEX AB

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.